Time (days) A % Overall Survival Time (days) % Overall Survival SUPPLEMENTAL FIGURE 1 Legend: MMTV-Cre, n = 71 R26(Pik3ca), n = 285 R26(Stat3), n = 46.

Slides:

Advertisements

Similar presentations

Overall Survival (months) Cumulative Survival (%) BM negative BM positive P = Supplemental file 5 Overall survivals.

Advertisements

RAS PI3’K AKT RAL-GEF U0126 PD98059 PD (CI-1040) proliferation survival proliferation / differentiation survival migration proliferation RAF MEK.

Supplemental Figure 1 A No. at risk T T T

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

University of British Columbia

Supplementary Data. β-actin IL-13Rα2 65 kDa 42 kDa G26-H2 G26-V2 SnB19-pcDNA SnB19-asIL-13Rα2 Figure S1A.

Supplemental Figure 1 Auranofin BSO Zn-BG ABC D carfilzomib.

Supplemental Figure Legends Supplemental Figure 1a: SF-36. SF-36 mental component score among subjects randomized to SAMe or placebo, at baseline, Week.

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Copyright © 2012 American Medical Association. All rights reserved.

Lung squamous cell carcinoma

Copyright © 2005 American Medical Association. All rights reserved.

From: An Externally Validated Model for Predicting Long-Term Survival after Exercise Treadmill Testing in Patients with Suspected Coronary Artery Disease.

Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive.

SIOP-E HR-MBL Hungarian Proposal

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Supplemental Figures Supplemental Figure 1.

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.

Volume 15, Issue 8, Pages (July 2014)

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab Marc Schnitzler, Jens Hasskarl,

!'!!. = pt >pt > \ ___,..___,..

Length bias Legend Screening Disease onset Slowly progressive disease

Table 2. Progression-Free Survival

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Suppl Table 1. Database has been randomly split in two groups

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis Sanjeev Kumar, Stanley L.-S. Fan, Martin.

Figure S1 Figure S2.

Supplemental Figure 1A Pt Pt Pre-treatment

FDA-Approved PI3K Inhibitors for CLL and FL

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Overview of the QTWiST method

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: A single-institution experience

CYCLE 1A Supplemental Figure

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Supplemental Figure 1 – Age Distribution in the CAC Consortium

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Robert.

Volume 73, Issue 1, Pages 5-7 (January 2008)

Statistical Considerations in Studies of Late Effects in HCT

Volume 92, Issue 3, Pages (September 2017)

Supplementary Figure 2A

Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma Javier Bolaños-Meade,

Volume 138, Issue 5, Pages e13 (May 2010)

Supplemental file 4 Disease free survivals of the entire cohort of patients A Disease Free Survival (months) Cumulative Survival (%) Disseminated.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease:

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

High volume Low volume HORRAD STAMPEDE Failure-free survival

Volume 71, Issue 12, Pages (June 2007)

Definition of health states

Low triiodothyronine and survival in end-stage renal disease

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Diagonal lines were shown.

Familial phenotype differences in PKD11

Supplemental Fig 1 (A) (B) (B) 59% % alive 52% Years from entry 59%

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma per health-insurance (NHIF) status at diagnosis (P=0.003). Kaplan-Meier.

Kaplan-Meier estimates of event-free survival in children with non-Hodgkin lymphoma (n=63). Kaplan-Meier estimates of event-free survival in children with.

Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders Martin Benesch, MD, H. Joachim.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Presentation transcript:

Time (days) A % Overall Survival Time (days) % Overall Survival SUPPLEMENTAL FIGURE 1 Legend: MMTV-Cre, n = 71 R26(Pik3ca), n = 285 R26(Stat3), n = 46 K-Ras(G12D), n = 10 R26(Pik3ca H1047R );MMTV-Cre, n = 112 R26(Stat3 C );MMTV-Cre, n = 30 R26(Pik3ca H1047R /Stat3 C );MMTV-Cre, n = 48 K-Ras(G12D);MMTV-Cre, n = 35 R26(Pik3ca H1047R );K-Ras(G12D);MMTV-Cre, n = 58 R26(Stat3 C );K-Ras(G12D);MMTV-Cre, n = 25 | = censored data B

ABC KA SC AME SC PDA AME SUPPLEMENTAL FIGURE 2 STC SC CAC SC

E545KNormal β-Actin Stat3 pY705 Erk1/2 pT202/204 42kDa 84kDa 42-4kDa H1047RRasE545K;RasH1047R;Ras SUPPLEMENTAL FIGURE 3 CACSTC SCC CAC Ras Stat3 C ;Ras A B

A) Relapse B) Survival Relapse free (%)Disease free survival (%) SUPPLEMENTAL FIGURE 4 PI3K+ Stat3 Pathways PI3K + Ras Pathways Stat3 + Ras Pathways PI3K + Stat3 + Ras Pathways PI3K+ Stat3 Pathways PI3K + Ras Pathways Stat3 + Ras Pathways PI3K + Stat3 + Ras Pathways Time (years)

A) Relapse (PI3K Pathway) C) Relapse (Stat3 Pathway) D) Death (Stat3 Pathway) Relapse free (%) B) Death (PI3K Pathway) Basal-like SUPPLEMENTAL FIGURE 5 Time (years)